![Philip Beales](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Philip Beales is the founder of Congenica Ltd.
(founded in 2013) and holds the title of Chief Medical Officer.
Mr. Beales is also the founder of Axovia Therapeutics, Inc., P4 Precision Medicine Accelerator.
Currently, Mr. Beales is a Professor at UCL Institute of Child Health.
Philip Beales active positions
Companies | Position | Start |
---|---|---|
Congenica Ltd.
![]() Congenica Ltd. BiotechnologyHealth Technology Congenica Ltd. develops genome-based discovery and diagnostic technologies. It uses Sapientia technology platform, which allows genome scale DNA sequence data to be presented within a clinically actionable diagnostic report. The company was founded by Matthew Hurles, Richard Durbin and Philip Beales in 2013 and is headquartered in Hinxton, the United Kingdom. | Founder | 01/01/2013 |
UCL Institute of Child Health | Corporate Officer/Principal | - |
P4 Precision Medicine Accelerator
![]() P4 Precision Medicine Accelerator Miscellaneous Commercial ServicesCommercial Services P4 Precision Medicine Accelerator is a private company that seeks out leading medtech startups to support through development, regulation, investment, adoption, and scale to UK and international markets to innovate and advance the healthcare landscape. The company is based in Sheffield, South Yorkshire, with a local, national, and international focus. The British company curates an ecosystem of physical space and specialists to support precision medicine innovations to develop research into world-leading technology, support to gain regulatory approval and adoption not only to the healthcare system but scale internationally. The company was founded by Philip Beales, Nathan McNally. | Founder | - |
Axovia Therapeutics, Inc.
![]() Axovia Therapeutics, Inc. BiotechnologyHealth Technology Part of Axovia Therapeutics Ltd., Axovia Therapeutics, Inc. is dedicated to developing disease-transformative therapies that target key aspects of ciliopathies. The American company is working to advance gene therapy programs that have already shown early promise in treating some of the most severe aspects of bbs, such as early onset blindness and neurometabolic disease. The company was founded by Philip Beales, Victor Hernandez, and Philip Beales has been the CEO since incorporation. Axovia Therapeutics was acquired by Alsa Management Services Ltd on September 19, 2023. | Chief Executive Officer | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
Congenica Ltd.
![]() Congenica Ltd. BiotechnologyHealth Technology Congenica Ltd. develops genome-based discovery and diagnostic technologies. It uses Sapientia technology platform, which allows genome scale DNA sequence data to be presented within a clinically actionable diagnostic report. The company was founded by Matthew Hurles, Richard Durbin and Philip Beales in 2013 and is headquartered in Hinxton, the United Kingdom. | Health Technology |
UCL Institute of Child Health | |
P4 Precision Medicine Accelerator
![]() P4 Precision Medicine Accelerator Miscellaneous Commercial ServicesCommercial Services P4 Precision Medicine Accelerator is a private company that seeks out leading medtech startups to support through development, regulation, investment, adoption, and scale to UK and international markets to innovate and advance the healthcare landscape. The company is based in Sheffield, South Yorkshire, with a local, national, and international focus. The British company curates an ecosystem of physical space and specialists to support precision medicine innovations to develop research into world-leading technology, support to gain regulatory approval and adoption not only to the healthcare system but scale internationally. The company was founded by Philip Beales, Nathan McNally. | Commercial Services |
Axovia Therapeutics, Inc.
![]() Axovia Therapeutics, Inc. BiotechnologyHealth Technology Part of Axovia Therapeutics Ltd., Axovia Therapeutics, Inc. is dedicated to developing disease-transformative therapies that target key aspects of ciliopathies. The American company is working to advance gene therapy programs that have already shown early promise in treating some of the most severe aspects of bbs, such as early onset blindness and neurometabolic disease. The company was founded by Philip Beales, Victor Hernandez, and Philip Beales has been the CEO since incorporation. Axovia Therapeutics was acquired by Alsa Management Services Ltd on September 19, 2023. | Health Technology |
- Stock Market
- Insiders
- Philip Beales